Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.43 |
| ▸ | PDE4A | P27815 | 8/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18208194 | 1.00 | PDE4B (0.43) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18208641 | 0.88 | NTRK1 (0.41) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18208638 | 0.88 | NTRK1 (0.41) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18209067 | 0.87 | PDE4B (0.45) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18209069 | 0.87 | PDE4B (0.45) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18208954 | 0.84 | PDE4B (0.46) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18208952 | 0.84 | PDE4B (0.46) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18208726 | 0.83 | NTRK1 (0.42) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18208727 | 0.83 | NTRK1 (0.42) | PDE4BPDE4DPDE4CPDE4AHSD11B1 | |
| SCHEMBL18208672 | 0.83 | HSD11B1 (0.44) | PDE4BPDE4DPDE4CPDE4AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | claimed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292107-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | PDE4B 3247/4885PDE4D 3793/4885PDE4C 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.